Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 6/20 | 0.40 |
| ▸ | BTK | Q06187 | 4/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | RHOA | P61586 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | STAT6 | P42226 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1025701 | 0.90 | ALDH1A1 (0.49) | ALDH1A1KDM4EGAAEGFRBTK | |
| SCHEMBL1025168 | 0.87 | NR3C2 (0.47) | ALDH1A1KDM4EGAAEGFRBTK | |
| SCHEMBL13623027 | 0.86 | SYK (0.44) | ALDH1A1KDM4EGAAEGFRBTK | |
| SCHEMBL1025950 | 0.85 | KDM4E (0.41) | ALDH1A1KDM4EGAAEGFRBTK | |
| SCHEMBL1024973 | 0.85 | CTSC (0.40) | EGFRBTKCTSCJAK3RHOA | |
| SCHEMBL1027584 | 0.84 | MAPT (0.51) | ALDH1A1GAAEGFRBTKJAK3 | |
| SCHEMBL13623028 | 0.83 | BCL6 (0.42) | ALDH1A1KDM4EGAAEGFRCTSC | |
| SCHEMBL1025084 | 0.83 | JAK3 (0.42) | EGFRBTKCTSCJAK3RHOA | |
| SCHEMBL4333056 | 0.83 | EGFR (0.41) | EGFRBTKCTSCJAK3MET | |
| SCHEMBL1023949 | 0.83 | ALDH1A1 (0.40) | ALDH1A1KDM4EGAAEGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | ALDH1A1 2511/4885KDM4E 248/4885GAA 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.